Reply to the letter to the editor'What is the clinical impact ofthe LUX-Lung 5 trial?' by Addeo

Schuler MCHIH-HSIN YANGPlanchard D.2020-05-262020-05-2620160923-7534https://www.scopus.com/inward/record.uri?eid=2-s2.0-84974817848&doi=10.1093%2fannonc%2fmdw144&partnerID=40&md5=1cf8bb970fc40c3b3bbc887650a56e88https://scholars.lib.ntu.edu.tw/handle/123456789/494977[SDGs]SDG3afatinib; epidermal growth factor receptor; erlotinib; gefitinib; osimertinib; paclitaxel; Article; cancer research; EGFR gene; gene mutation; human; metastasis; monotherapy; non small cell lung cancer; phase 3 clinical trial (topic); priority journal; progression free survival; randomized controlled trial (topic); relapse; lung; lung tumor; non small cell lung cancer; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung NeoplasmsReply to the letter to the editor'What is the clinical impact ofthe LUX-Lung 5 trial?' by Addeojournal article10.1093/annonc/mdw144270297032-s2.0-84974817848